Abstract: Biomolecular sensors and methods of manufacturing these sensors are provided. An exemplary sensor has a source electrode, a drain electrode spaced apart from the source electrode by a sensor gap, a gate electrode, wherein the source, drain and gate electrodes cooperate to form an electrode circuit, a bridge bridging across said sensor gap coupling the source and drain electrodes, and a probe coupled to the bridge, wherein the probe comprises nucleic acid and interaction of the nucleic acid probe with a target nucleic acid is detectable by monitoring at least one parameter of the electrode circuit. Methods of detecting a target nucleic acid are also provided. Preferred target nucleic acids that are detected are from pathogens, such as coronavirus.

Abstract: A molecular electronics sensor capable of performing genetic analysis is described. In various embodiments, the sensor comprises spaced-apart electrodes, a bridge molecule coupled to the electrodes, and an oligonucleotide hybridization probe conjugated to the bridge molecule. The hybridization probe may comprise an oligonucleotide sequence complementary to a segment of a pathogen genome to be detected. In various aspects, a plurality of such sensors are disposed as an array of pixels on a CMOS chip. Sensors herein can be configured to detect a segment of SARS-CoV-2 genome in a bio-sample.

Abstract: A molecular electronics sensor capable of performing genetic analysis is described. In various embodiments, the sensor comprises spaced-apart electrodes, a bridge molecule coupled to the electrodes, and an oligonucleotide hybridization probe conjugated to the bridge molecule. The hybridization probe may comprise an oligonucleotide sequence complementary to a segment of a pathogen genome to be detected. In various aspects, a plurality of such sensors are disposed as an array of pixels on a CMOS chip. Sensors herein can be configured to detect a segment of SARS-CoV-2 genome in a bio-sample.

Abstract: The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway.

Abstract: The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway.

Abstract: The present invention relates to the use of SNPs in predicting susceptibility and/or severity of Multiple Sclerosis in an individual. The SNPs are located in the introns of the glycosylation enzymes MGAT5 and XYLT1, 3? of HIF1AN, within introns of MEGF11. FGF14, PDE9A and CDH13 and within desert regions of 4q34 and 17p13.

Abstract: The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway.

Abstract: The present invention relates to EPO polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.

Abstract: The invention concerns the genomic DNA, cDNA, and polypeptide sequences of CanIon, a novel voltage gated ion channel protein. The invention also concerns biallelic markers of the CanIon gene. The CanIon gene may be used as a biological target for the treatment and diagnosis of schizophrenia, bipolar disorder, and other diseases and conditions.

Abstract: The invention relates to the use of PP2A/B? and to the use of a PP2A phosphatase comprising the PP2A/B? subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The invention also discloses biallelic markers located in the gene encoding PP2A/B? and their use for diagnosing mental disorders.

Abstract: The invention relates to the use of PP2A/B&ggr; and to the use of a PP2A phosphatase comprising the PP2A/B&ggr; subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The present invention further provides novel PP2A/B&ggr; subunits generated by alternative splicing events. The invention also discloses biallelic markers located in the gene encoding PP2A/B&ggr; and their use for diagnosing mental disorders.

Abstract: The invention concerns the genomic DNA, cDNA, and polypeptide sequences of CanIon, a voltage gated ion channel protein. The invention also concerns biallelic markers of the CanIon gene. The CanIon gene may be used as a biological target for the treatment and diagnosis of schizophrenia, bipolar disorder, and other diseases and conditions.

Abstract: The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.